✓ Plata cu cardul restabilită — finalizare securizată prin Privacy Shield

Etibo

✅ Targets cancer cells
✅ Inhibits tumor growth
✅ Treats breast cancer
✅ Blocks HER2 receptors
✅ Improves survival rates

Etibo contains Lapatinib.

Verificat medical de Morgan Ellis — Cercetător farmaceutic · 8 ani de experiență  · Ultima recenzie: mai 2026

Cumpără mai mult, economisește mai mult Preț pe tabletă
30 tablete
US$4.83/tablet
US$145.00
60 Comprimat/e
US$4.73/tablet · save 2%
US$284.00
90 Tabletă/tablete
US$4.67/tablet · save 3%
US$420.00
180 Tablete CEA MAI BUNĂ OFERTĂ
US$4.17/tablet · economisiți 14%
US$750.00
Plată criptată
Plățile în crypto reduc prețul cu 10%
Livrare discretă în întreaga lume
1.400+ clienți · 50+ țări

💡 Răspuns rapid

Etibo este lapatinib 250 mg, un dual HER2/EGFR tyrosine kinase inhibitor for advanced or metastatic HER2-positive breast cancer. Oral once-daily therapy combined with capecitabine or other regimens, usually after trastuzumab (Herceptin) failure. Significant side effects include diarrhoea, rash, and cardiotoxicity; requires close oncologist supervision and ECG monitoring.

Ce beneficii oferă MedsBase: Producător certificat WHO-GMP · Ambalaj discret · Livrare la nivel mondial · Peste 1.400 de recenzii verificate ale clienților

📦 Fiecare comandă este acoperită de politica noastră de Politica noastră de Reexpediere Garantată — dacă coletul dumneavoastră nu sosește în 20 de zile lucrătoare, îl relivrăm.

De ce să comanzi de la MedsBase

Medicamentele noastre generice sunt procurate de la producători certificați WHO-GMP și expediate la nivel mondial în ambalaje discrete și simple — fără denumirea medicamentului pe exteriorul coletului. Plățile cu cardul sunt procesate printr-un procesor reglementat (descrierile de pe extrasul de cont includ un procesor de plăți cu card reglementat — niciodată “MedsBase” sau numele vreunui medicament). Acceptăm și criptomonede și transferuri bancare SEPA. Fiecare comandă este susținută de Politica noastră de Asigurare pentru Relivrare.

🔒 Why order from MedsBase: Verified genuine manufacturer supply · Worldwide Shipping · Secure checkout (credit card, crypto) · Rated 4.9★ by 1,400+ customers

What Is Etibo?

Etibo is a branded generic of lapatinib 250 mg, a small-molecule tyrosine kinase inhibitor that targets HER2 (ErbB2) și EGFR (ErbB1). Lapatinib blocks intracellular signaling downstream of these receptors, halting proliferation of HER2-positive cancer cells. Manufactured by Natco Pharma.

Critical: Lapatinib is an oncology drug used only under specialist supervision. It is not a general women’s health product. Use strictly according to oncologist protocol — typically after trastuzumab resistance develops.

Utilizări clinice

  • Advanced/metastatic HER2+ breast cancer: 1250 mg daily (5 tablets) + capecitabine — after trastuzumab failure.
  • HER2+ breast cancer with letrozole in postmenopausal women with ER+/HER2+ metastatic disease.
  • Not indicated for adjuvant (early-stage curative) therapy — trastuzumab ± pertuzumab remain standard there.

Cum se administrează

  1. Luați 1250 mg (5 tablets) once daily, at least 1 hour before or after food. Food significantly increases absorption and shifts dosing parameters; consistency matters.
  2. Typical partner drug: capecitabine 2000 mg/m²/day on days 1–14 of a 21-day cycle.
  3. ECG and LVEF monitoring at baseline and every 3 months (cardiotoxicity risk).
  4. Manage diarrhoea proactively — often grade 1–3, common in first cycle. Loperamide, hydration, dose reduction as needed.
  5. Avoid grapefruit, Seville oranges, and CYP3A4 inhibitors/inducers.

Efecte Secundare

Foarte frecvente: diarrhoea (60–80%), rash (40–60%), nausea, vomiting, fatigue, hand-foot syndrome, palmar-plantar erythrodysesthesia (with capecitabine combo).

Significant: hepatotoxicity (monitor LFTs), cardiotoxicity / reduced LVEF (5–6%), QT prolongation, interstitial lung disease (rare but serious).

Serious: severe liver injury, heart failure, severe skin reactions (Stevens-Johnson), pulmonary toxicity.

Who Should Not Take Etibo

  • HER2-negative breast cancer (ineffective)
  • Severe hepatic impairment
  • Symptomatic heart failure or severe cardiac dysfunction
  • Pregnancy — teratogenic
  • Concurrent strong CYP3A4 inhibitors or inducers without dose adjustment

Interacțiuni medicamentoase

  • Inhibitori puternici ai CYP3A4 (ketoconazole, ritonavir, clarithromycin, grapefruit): raise lapatinib levels significantly.
  • Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John’s Wort): reduce lapatinib levels and efficacy.
  • PPIs, H2 blockers: reduce absorption — avoid or space by hours.
  • Warfarin, digoxin: may increase levels.

Depozitare

Store at room temperature (15–30 °C), away from moisture. Keep in original packaging. Keep out of reach of children.

Întrebări frecvente

When is lapatinib used?

Advanced/metastatic HER2-positive breast cancer, typically after trastuzumab (Herceptin) resistance. Not used for early-stage curative therapy.

Why take on empty stomach?

Food increases lapatinib absorption 4–5×, making dosing unpredictable. Standard is consistent fasting — 1 hour before or after food — at a fixed time each day.

How bad is the diarrhoea?

Common, often grade 1–2; manageable with loperamide and hydration. Grade 3+ diarrhoea may require treatment interruption and dose reduction. Report early.

Will lapatinib damage my heart?

About 5–6% of patients have asymptomatic LVEF drops. ECG + echocardiogram at baseline and every 3 months. Usually reversible on dose adjustment or interruption.

Can I take lapatinib with trastuzumab?

Combination lapatinib + trastuzumab is used in specific protocols. Not routine without oncologist supervision.

What about fertility?

Effective contraception required during treatment and for 1 week after (teratogenic). Men should use effective contraception during and 3 months after.

Why is this in the Women's Health category?

HER2+ breast cancer disproportionately affects women (though rarely men get HER2+ breast cancer). Categorisation reflects the population, not a strict clinical cluster.

Is lapatinib still first-line?

For second-line HER2+ metastatic disease (after trastuzumab), lapatinib + capecitabine was standard for years. Newer options (T-DM1/Kadcyla, T-DXd/Enhertu, tucatinib) have since largely supplanted it in first-world oncology — lapatinib remains important where newer agents are unavailable.

Related Women’s Health Products

⚕️ Disclaimer medical: Information is educational and does not replace medical advice. Consult a clinician before starting, stopping, or changing any medication, particularly for cancer therapy, hormonal treatments, and prescription products.

Alternative conexe

Other oncology medications stocked alongside this product:

More options in Anti Cancer Medication

Clasificate în funcție de volumul recent de comenzi MedsBase — ce aleg alți clienți în această categorie.

Concentrație

250 mg

Cantitate

30 Comprimat/e, 60 Comprimat/e, 90 Comprimat/e, 180 Comprimat/e

Recenzii

Nu există recenzii încă

Adăugați o recenzie
Etibo Etibo
Evaluare*
0/5
* Evaluarea este obligatorie
* Răspunsul este obligatoriu
Recenzia dvs.
* Recenzia este obligatorie
Nume
* Numele este obligatoriu
Adăugați fotografii sau videoclip la recenzia dvs.

Întrebări și răspunsuri

Pune o întrebare
Etibo Etibo
Întrebarea ta
* Întrebarea este obligatorie
Nume
* Numele este obligatoriu
Nu există întrebări încă